The trial will use two types of antibiotics: Erythromycin and Neomycin. Erythromycin is a commonly used antibiotic that helps fight bacterial infections, and Neomycin is another antibiotic that works similarly. Both medications will be given in tablet form to be taken by mouth. Some participants in the study will receive these antibiotics, while others will receive a placebo, which looks like the real medication but does not contain any active ingredients.

The purpose of the study is to determine if taking these antibiotics before surgery, without the need for mechanical bowel preparation (a process to clean out the intestines), can lower the chances of getting a surgical site infection. Participants will be monitored throughout their hospital stay and after surgery to check for any infections or complications. The study will help understand the effectiveness of this approach in reducing infections and improving recovery after colorectal surgery.

Participants in the study will receive the treatment through a method called topical application, which means it is applied directly to the skin. The study will last up to 10 weeks, during which time the healing process of the wound will be closely monitored. Researchers will look for any changes in the wound’s condition and check if the infection is cleared. The study will also track any reactions to the treatment, both at the site of application and throughout the body.

The trial aims to provide valuable information on how well DUOFAG® works in treating surgical wound infections and whether it is safe for patients. By the end of the study, researchers hope to determine if this treatment can be a reliable option for managing infections caused by Staphylococcus aureus and Pseudomonas aeruginosa in surgical wounds.

Participants in the study will be randomly assigned to one of two groups. One group will receive the standard care after surgery, while the other group will receive the standard care plus the D-PLEX treatment. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the additional treatment, to ensure unbiased results. The main goal is to observe whether D-PLEX can reduce the rate of infections at the surgical site within 30 days after the operation.

The trial will take place over a period of time, with participants being monitored for any signs of infection or other health issues following their surgery. The safety of D-PLEX will also be closely watched to ensure it does not cause any harmful effects. This study is part of a larger effort to improve recovery and outcomes for patients undergoing abdominal surgery by potentially offering a new way to prevent post-surgical infections.